Wall Street brokerages forecast that ZIOPHARM Oncology Inc (NASDAQ:ZIOP) will report $1.59 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for ZIOPHARM Oncology’s earnings. The highest sales estimate is $1.70 million and the lowest is $1.46 million. ZIOPHARM Oncology reported sales of $1.70 million in the same quarter last year, which would suggest a negative year over year growth rate of 6.5%. The firm is scheduled to issue its next earnings report after the market closes on Monday, July 31st.

On average, analysts expect that ZIOPHARM Oncology will report full year sales of $1.59 million for the current fiscal year, with estimates ranging from $5.99 million to $7.00 million. For the next financial year, analysts anticipate that the firm will post sales of $5.81 million per share, with estimates ranging from $3.00 million to $8.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, May 1st. The biotechnology company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.03. The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.71 million. The firm’s revenue for the quarter was down 18.8% on a year-over-year basis.

Several equities analysts recently weighed in on the company. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. HC Wainwright assumed coverage on ZIOPHARM Oncology in a research note on Thursday, June 1st. They issued a “buy” rating and a $9.50 price objective for the company. Finally, Zacks Investment Research raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, April 26th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $13.00.

TRADEMARK VIOLATION NOTICE: “ZIOPHARM Oncology Inc (ZIOP) Expected to Post Quarterly Sales of $1.59 Million” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/26/ziopharm-oncology-inc-ziop-expected-to-post-quarterly-sales-of-1-59-million.html.

A number of large investors have recently made changes to their positions in the stock. Mission Wealth Management LLC bought a new stake in shares of ZIOPHARM Oncology during the first quarter worth approximately $108,000. Highbridge Capital Management LLC bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter worth approximately $164,000. Old West Investment Management LLC bought a new stake in shares of ZIOPHARM Oncology during the first quarter worth approximately $205,000. UBS Asset Management Americas Inc. boosted its stake in shares of ZIOPHARM Oncology by 79.6% in the first quarter. UBS Asset Management Americas Inc. now owns 37,687 shares of the biotechnology company’s stock worth $239,000 after buying an additional 16,700 shares during the period. Finally, Private Advisor Group LLC boosted its stake in shares of ZIOPHARM Oncology by 23.4% in the first quarter. Private Advisor Group LLC now owns 41,541 shares of the biotechnology company’s stock worth $260,000 after buying an additional 7,875 shares during the period. Hedge funds and other institutional investors own 38.05% of the company’s stock.

ZIOPHARM Oncology (NASDAQ ZIOP) traded down 0.17% during midday trading on Wednesday, hitting $5.96. 519,008 shares of the stock traded hands. The stock’s market cap is $778.98 million. The company has a 50-day moving average of $5.91 and a 200-day moving average of $6.35. ZIOPHARM Oncology has a 12 month low of $4.55 and a 12 month high of $7.88.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.